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The present study is an extension of our previous work carried out on Cynodon dactylon. This
study deals with the critical evaluation of glycemic potential of ethanolic extract of defatted
C. dactylon. The doses of 250, 500 and 750mgkg
 1 bw of the extract were administered orally
to normal as well as Streptozotocin-induced diabetic rats to study its glycemic potential. The
effect of repeated oral administration of the same doses of ethanolic extract was also studied on
serum lipid profile of severely diabetic (SD) rats. The dose of 500mgkg
 1 bw was identified as
the most effective dose as it lowered the blood glucose levels of normal by 42.12% and of
diabetic by 43.42% during fasting blood glucose (FBG) and glucose tolerance test respectively.
The SD rats were also treated daily with this identified dose of 500mgkg
 1 bw for 2 weeks and
a significant reduction of 56.34% was observed in FBG level. Total cholesterol, low density
lipoprotein and triglyceride levels were also decreased by 32.94, 64.06 and 48.46% respectively
in SD rats whereas, cardioprotective high density lipoprotein increased by 16.45%. The reduced
urine sugar level and increased body weight are additional advantages. These evidences clearly
indicate that the ethanolic extract of defatted C. dactylon has high antidiabetic potential along
with good hypolipidemic profile.
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Introduction
Diabetes, a global burden, is characterized by fast
elevation of blood sugar level. The incidence of diabetes
mellitus is rising all over the world, especially in Asia.
Many oral hypoglycemic agents, such as biguanides and
sulfonylurea are available along with insulin for the
treatment of diabetes mellitus but they have significant
side effects (1,2) and sometimes they are found to be
ineffective in chronic diabetic patients (3). Thus, there is
an increasing demand of natural and synthetic products
with high antidiabetic potential and lesser side effects (4).
The researches conducted over the last several decades
have shown that plant and plant-based therapies have
high potential to treat and control diabetes (5–7) and its
complications (8). Therefore, search for safe and more
effective agents has continued to be an important area of
active research. Since ancient times, diabetes has been
treated orally with several medicinal plants or their
extracts, based on folklore medicine. These herbal
remedies are apparently effective, produce minimal or
no side effects and are of relative low costs as compared
to oral synthetic hypoglycemic agents. Furthermore, after
the recommendation made by WHO on diabetes mellitus,
investigation of hypoglycemic agents from medicinal
plants have become more important (9–11).
Cynodon dactylon (Fam: Poaceae) is commonly known
as ‘Doob’ in India. It is a weed and has been regarded to
possess varied medicinal properties. It has been used to
treat urinary tract infection, calculi and prostatitis. The
plant possesses antimicrobial and antiviral activity (12).
The aqueous fluid extract of the rhizome is used as anti-
inflammatory, diuretic, anti-emetic, purifying agent and
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properly cited.also in dysentery (13,14). The plant extract also has
significant application in dropsy and secondary syphilis
(15). The plant is traditionally used as an agent to control
diabetes in India (16,17). The present investigation was
therefore carried out to evaluate the traditional use of
C. dactylon scientifically. Since the aqueous extract of
C. dactylon was found to have high antidiabetic potential
(18), the study of its ethanolic extract was therefore
undertaken to exploit further its antidiabetic potential in
Streptozotocin (STZ)-induced diabetic rats.
Methods
Preparation of Ethanolic Extract
Cynodon dactylon was collected from the campus of
University of Allahabad, Allahabad, India. It was
identified and authenticated by Botanical Survey of
India, Allahabad branch and Prof. B.D. Singh, taxono-
mist, Allahabad Agriculture Institute, Naini, Allahabad.
A voucher specimen (AA518) has been submitted. The
whole green plant was washed with water and shade-
dried. About 500g of shade-dried plant was treated with
hexane (2 2.5l) to defat it and then extracted with
ethanol (3l) for 48h. The resulting extract was filtered
and concentrated in rotavapor under reduced pressure
to give a residue (yield about 10.8% w/w) for further
exploration.
Experimental Animals
Male albino wistar rats of same age group and body
weight 150–200g were selected for all the experiments.
Animals obtained from National Institute of
Communicable Disease (NICD), New Delhi, India, were
housed in polypropylene cages at an ambient temperature
of 25–30 C and 45–55% relative humidity with a 12h
each of dark and light cycle. Rats were fed pellet diet
(Golden feed, New Delhi India) and water ad libitum.
The study was approved by the Institutional Ethical
Committee (83 a/a/04/CPCSEA).
Induction of Diabetes in Rats
Diabetes was induced by a single intraperitonial injection
of freshly prepared STZ (50mgkg
 1 bw) in 0.1M citrate
buffer (pH¼4.5) to overnight fasted rats. After 3 days of
STZ administration, rats with marked hyperglycemia
(fasting blood glucose (FBZ)4150mgdl
 1) were selected
for the study. The rats with hyperglycemia were divided
into two groups.
  Mild diabetic (MD) rats with FBG 120–250mgdl
 1.
  Severely diabetic (SD) rats showing FBG above
250mgdl
 1.
Estimation
Blood glucose level (BGL), total cholesterol (TC), high
density lipoprotein (HDL) cholesterol and triglycerides
(TG) levels were estimated using standard kits of Bayer
diagnostics, India. Low density lipoprotein (LDL) and
very low density lipoprotein (VLDL) cholesterol levels
were calculated from the above measurement by using
Friedwald formula (19). Urine sugar was detected by
reagent-based Uristix from Bayer Diagnostics.
VLDL¼TG/5
LDL¼TC (HDLþTG/5)
Experimental Design
Evaluation of Glycemic Management in Normal
Healthy Rats
Twenty-four normal healthy male rats were fasted over-
night and divided equally into four groups of six rats
each. Pretreatment FBG levels of each group were
estimated. Group I served as untreated control given
vehicle (water only) whereas, other three groups II, III
and IV were given the powder of concentrated ethanolic
extract suspended in distilled water (DW) orally in doses
of 250, 500 and 750mgkg
 1 bw respectively. Blood
samples were collected from the tail vein after 2, 4 and
6h and percentage of hypoglycemia variations were
calculated for each group.
Glycemic Potential Assessment by Glucose
Tolerance in MD Rats
The hypoglycemic effect of ethanolic extract was eval-
uated in MD rats by glucose tolerance test. The overnight
fasted rats were divided into four groups V, VI, VII and
VIII of six rats each. Pretreatment FBG levels of each
group were estimated. Group V (Diabetic control)
received vehicle (water only) whereas, variable doses of
250, 500 and 750mgkg
 1 bw of ethanolic extract were
given orally to groups VI, VII and VIII respectively.
BGL of each group was further estimated after 90min of
the treatment considered as 0h value. About 2gkg
 1 bw
glucose was given to all the groups and their BGLs were
estimated hourly up to 2h after glucose administration
for evaluating glycemic potential.
Study of Antidiabetic and Antilipidemic Attributes
in SD Rats
The study was carried on three groups IX, X and XI of
six rats each. Group IX served as normal healthy control,
group X as diabetic control and group XI was orally
treated daily up to 2 weeks with a single dose of
500mgkg
 1 bw of ethanolic extract suspended in DW.
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only. FBG, TC, HDL cholesterol and TG levels were
estimated, before and after the treatment, weekly up to 2
weeks; LDL and VLDL cholesterol levels were also
calculated.
Estimation of Urine Sugar and Body Weight in SD Rats
Urine sugar and body weight were also assessed as
additional observations in groups X and XI before and
after the treatment, weekly up to 2 weeks.
LD50 Experiment
Toxic effect of the water extract was also studied by LD50
experiment. Two groups of rats of both the sexes
(six animals per group, three females and three males),
weighing about 180–200g were orally administered by
a single dose of 10.0g and 15.0g of the defatted ethanolic
extract of C. dactylon. Then rats were observed for
gross behavioral neurologic, autonomic and toxic
effects continuously. Food consumption, faeces and
urine were also examined at 2h and then at 6h intervals
for 24h.
Statistical Analysis
Data were statistically evaluated using one-way ANOVA,
followed by a post hoc Scheffe’s test using the SPSS
computer software, version 7.5. The values were con-
sidered significant when P50.05.
Results
Impact of Ethanolic Extract on FBG in Normoglycemic
Rats
Table 1 represents the hypoglycemic impact of graded
doses of ethanolic extract of defatted C. dactylon on
BGLs of normal healthy rats. All the three doses of 250,
500 and 750mgkg
 1 bw of the extract produced
a significant fall of 40.4, 47.1 and 39.4% respectively,
BGL after 4h of oral administration indicating thereby
a clear hypoglycemic impact. The highest impact was
marked in the animals treated with a dose of 500mgkg
 1
bw. Hence this dose was identified as the most effective
dose for critical evaluation of glycemic potential in case
of SD models.
Glycemic Potential of Ethanolic Extract on GTT in MD rats
Fig. 1 depicts the effect of graded doses of 250, 500 and
750mgkg
 1 bw of defatted C. dactylon ethanolic extract
on glucose tolerance up to 2h in MD rats. This helps in
deciding the dose of 500mgkg
 1 bw as the most effective
dose for the study of severely diabetic models. The fall
observed in BGL after 2h of glucose administration was
10.2, 39.8 and 27.7% with the doses of 250, 500 and
750mgkg
 1 bw respectively. Since, the initial fall found
at 1h was 13.2, 43.9 and 25.3% from doses 250, 500 and
750mgkg
 1 bw respectively, suggesting thereby that
500mgkg
 1 bw is the most effective dose for assessing
the antidiabetic potential of ethanolic extract in SD
animals.
Table 1. Hypoglycemic impact of graded doses of ethanolic extract of C. dactylon in normal rats (mean S.D.)
BGLs (mgdl
 1)
Experimental animals Treatment Pretreatment levels Post-treatment levels
FBG 2h 4h 6h
Control DW 84.6 3.5 83.2 2.7 82.7 3.5 80.6 3.6
Treated 250mgkg
 1 81.5 6.5 62.5 4.4 48.5 4.2* 68.3 4.5*
Treated 500mgkg
 1 78.3 4.5 57.7 3.5 41.4 4.5* 57.2 6.5
Treated 750mgkg
 1 78.8 7.5 61.0 6.4 47.7 4.5* 63.4 4.3*
*P50.01 as compared to pretreatment level.
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Figure 1. Hypoglycemic impact of graded doses of ethanolic extract of
C. dactylon on glucose tolerance in mild diabetic rats. *P50.01 as
compared to control.
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The impact of repeated oral administration of defatted
C. dactylon ethanolic extract on FBG and lipid profile of
SD rats is shown in Table 2. FBG levels remain
practically the same before and after the treatment with
vehicle (water only) in case of normal control rats.
Whereas, in diabetic control rats the FBG rises gradually
in 2 weeks after treatment with vehicle (water only).
Moreover, the 2-week treatment with the most effective
dose (500mgkg
 1 bw) of the extract decreases FBG
significantly from 310.6mgdl
 1 to 135.6mgdl
 1 indicat-
ing thereby a fall of 56.3% in BGL. This sharp fall of
56.3% in BGL is a clear evidence of significant
antidiabetic effect of defatted C. dactylon. A distinct
lowering of TC level of 32.9% was also observed with
this most effective dose after two weeks. TG level also
showed a significant reduction of 48.4% in the extract-
treated group. The interesting observation was an
increase of 16.4% in HDL level with a decrease of 64%
in LDL after treatment.
Effect of Ethanolic Extract on Urine Sugar and Body
Weight in SD Rats
Table 3 and Fig. 2 reveal the impact of the most effective
dose of 500mgkg
 1 bw of defatted C. dactylon ethanolic
extract on urine sugar levels and body weights respec-
tively of SD rats along with normal control rats. It has
been observed that the urine sugar level decrease about
75% and body weight increases about 13% after the
treatment of 2 weeks.
LD50
Experiments were carried out on normal healthy rats.
The behavior of the treated rats appeared normal.
No toxic effect was reported at doses up to 10 and
15 times of the effective dose of the ethanolic extract
as no mortality was observed in any of these groups.
Discussion and Conclusion
The findings of this study indicate that the graded doses
of 250, 500 and 750mgkg
 1 bw of the ethanolic extract
of defatted C. dactylon had a significant hypoglycemic
effect of 40.4, 47.1 and 39.4% after 4h of treatment in
normal rats. The effect was dose-dependent up to
500mgkg
 1 bw. However, the response decreased at
higher dose of 750mgkg
 1 bw. Such a phenomenon of
less hypoglycemic response at higher doses is common in
indigenous plants and has already been observed in
Momordica cymbalaua (20), Aegle marmelose (21) and
Vinca rosea (22).
The glucose tolerance test (GTT) studies of the MD
animals reveal a maximum fall of 43.9% within 1h by the
Table 2. Impact of oral administration of the ethanolic extract of C.
dactylon on FBG and lipid profile in SD rats (mean S.D.)
Experimental
animals
Treatment Pretreatment
levels
Post-treatment
levels
FBG (mgdl
 1)
Normal (control) DW 90.2 4.5 94.5 5.6*
SD (control) DW 280.6 5.7 301.4 5.4*
SD (treated) 500mgkg
 1 310.6 7.5 135.6 2.5*
TC (mgdl
 1)
Normal (control) DW 57.8 5.4 64.6 8.4*
SD (control) DW 117.6 6.4 130.8 3.2*
SD (treated) 500mgkg
 1 120.5 3.8 80.8 6.5*
HDL cholesterol (mgdl
 1)
Normal (control) DW 30.7 3.2 32.8 4.6**
SD (control) DW 44.8 2.8 27.2 5.6**
SD (treated) 500mgkg
 1 38.6 3.5 46.2 7.5**
TG (mgdl
 1)
Normal (control) DW 85.3 3.5 88.4 4.5*
SD (control) DW 142.5 3.2 156.7 4.1*
SD (treated) 500mgkg
 1 146.3 2.7 75.4 4.2*
LDL cholesterol (mgdl
 1)
Normal (control) DW 10.0 5.8 14.1 7.4*
SD (control) DW 44.3 6.2 72.2 8.7*
SD (treated) 500mgkg
 1 52.6 4.2 18.9 5.2*
*P50.001 as compared to pretreatment levels.
**P50.05 as compared to pretreatment levels.
Table 3. Impact of the most effective dose of C. dactylon ethanolic
extract on urine sugar in SD rats (mean S.D.)
Experimental
animals
Treatment Pretreatment
levels
Post-treatment
levels
Normal (control) DW Nil Nil
SD (control) DW þþþþ þþþþ
SD (treated) 500mgkg
 1 þþþþ þ
*P50.001 as compared with pretreatment.
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Figure 2. Impact of the most effective dose of C. dactylon ethanolic
extract on body weight in SD rats. *P50.001 as compared with
pretreatment.
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 1 bw whereas, the doses of
250mgkg
 1 bw and 750mgkg
 1 bw produced a fall of
about 13.2 and 25.3% only in 1h in BGL. Since this
maximum fall was sustained by the dose of 500mgkg
 1
even after 2h of glucose administration in comparison to
other doses, therefore, the suggested effective dose for the
study of SD animals was found to be 500mgkg
 1 bw.
The results of GTT of normoglycemic animals observed
were on similar pattern verifying thereby the dose of
500mgkg
 1 as the most effective dose and therefore
a dose of choice for the study of severe cases. This
suggested and verified effective dose showed a marked
decrease in FBG level of 56.3% in SD animal after 2
weeks treatment, among all other doses used.
It has been observed mostly that hyperlipidemia has
been reported to accompany hyperglycemia states (23)
and the most common lipid abnormality observed is
hypertriglyceridemia. The marked hyperlipidemia that
characterizes the STZ-diabetic rats seems to be a
consequence of uninhibited action of lipolytic hormones
on adipose tissue. Since insulin inhibits adipose tissue
hormone sensitive lipase and reduces lipolysis,
C. dactylon may mimic insulin action. The dose of
500mgkg
 1 bw of the ethanolic extract not only lowered
the TC, TG and LDL levels by 32.9, 48.4 and 64% but
also enhanced the level of cardio protective HDL
cholesterol by 16.4% after 2 weeks of treatment.
Several studies showed that an increase in HDL
cholesterol is associated with a decrease in coronary
risk and most of the drugs that decrease TC also decrease
HDL cholesterol (24). It is important to note that in the
present study the ethanolic extract not only decreased the
TC but also increased the HDL cholesterol significantly
after 2 weeks treatment as an additional advantage
over the existing drugs. Since diabetes is associated with
coronary complications (25), which is the major cause of
morbidity and deaths in diabetic subjects (26,27) due to
high levels of TC and more importantly LDL cholesterol,
intake of ethanolic extract of defatted C. dactylon will
therefore help in reducing the incidence of coronary
events.
It has been reported recently that TG level is
independently related to coronary heart disease (28,29)
and most of the antihypercholesterolemic drugs do not
decrease TG levels (30,31). This study clearly shows that
the most effective dose of 500mgkg
 1 bw of the
ethanolic extract decreases TG level also by 48.8% after
2 weeks treatment.
From this study we can conclusively state that defatted
C. dactylon ethanolic extract has significant hypoglycemic
as well as antidiabetic effects on BGLs of normal, mild
and severely diabetic models. A substantial improvement
on hyperlipidemia due to diabetes was also observed.
Its unique effect of increasing HDL level about 16.4%
has additional advantage of reducing coronary risk.
Further characterizations of active components in
C. dactylon are warranted and studies are in progress
to isolate, identify and characterize active components.
These results suggest that the product of C. dactylon
may provide a new therapeutic avenue against diabetes
and diabetes-related complications—a global burden.
Moreover, natural health products of vegetable origin
were clearly indicated as a promising avenue for the
prevention of chronic diseases (32), as raised notably
by a panel of experts that convened in Montreal in
2004 (33). Wide-spread research is currently taking place
in China, India and other countries too in order to
explore new traditional Chinese, Indian and Western
medicines that will prevent and treat diabetes mellitus
and its chronic complications (34–36).
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